<DOC>
	<DOCNO>NCT03082742</DOCNO>
	<brief_summary>Chronic kidney disease ( CKD ) patient often associate systemic hypertension due volume retention , one mechanism , therefore use diuretic widespread population . One major complication CKD mineral bone metabolism disorder ( CKD-MBD ) , include change level calcium , phosphorus , vitamin D deficiency , increase circulating level fibroblast growth factor ( FGF-23 ) parathyroid hormone ( PTH ) . These alteration responsible fracture , cardiovascular disease mortality among patient CKD . According diuretic mechanism action , sometimes increase serum calcium ( case furosemide ) , sometimes decrease ( case thiazide ) , expect serum calcium may alter , even within range normality , consequent impact level PTH . Although study show use thiazide diuretic decrease risk fracture , show opposite . Similarly , although study show increased risk fracture association loop diuretic use , fail demonstrated outcome . Only one study , cohort study population CKD , show furosemide directly relate increase calciuria PTH level use thiazide , turn , show completely opposite effect . However , certain issue still completely solve , example , interference renal function calciuria . It possible calciuria simple explanation justifies PTH level change , correlation see calciuria PTH level . Better understand exact relationship use diuretic impact CKD-MBD may alternative intervention , easily accessible relatively inexpensive . The purpose study evaluate impact diuretic , specifically hydrochlorothiazide furosemide , bone architecture mineral metabolism .</brief_summary>
	<brief_title>The Effect Diuretics Mineral Bone Disorder Chronic Kidney Disease Patients</brief_title>
	<detailed_description>This prospective randomized study test effect thiazide furosemide bone parameter , assess peripheral micro-tomography baseline 12 month later . The role calciuria possible change test .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Bone Diseases</mesh_term>
	<mesh_term>Furosemide</mesh_term>
	<mesh_term>Diuretics</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Estimated Glomerular Filtration Rate ( calculate CKDEPI ) 30 60 ml/min Diabetes ; chronic use : steroid , bisphosphonates calcium carbonate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>diuretic</keyword>
	<keyword>furosemide</keyword>
	<keyword>hydrochlorothiazide</keyword>
	<keyword>CKD-MBD</keyword>
	<keyword>peripheral micro-CT</keyword>
	<keyword>parathyroid hormone</keyword>
</DOC>